|
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Human brain tumors that were highly resistant to ACNU, such as glioblastoma Gbl1 and metastatic brain tumor Col1 with SD10 values (microM) of above 100, expressed markedly increased amounts of 0.95 kb MGMT mRNA.
|
1518162 |
1992 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bacterial O6-methylguanine-DNA methyltransferase reduces N-methyl-N'-nitro-N-nitrosoguanidine induction of plasminogen activator in Mer- human glioblastoma A1235 cell line.
|
9678063 |
1998 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A genotype of the polymorphic DNA repair gene MGMT is associated with de novo glioblastoma.
|
14669534 |
2003 |
|
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
This prospective clinical trial identifies MGMT-methylation status as an independent predictor for glioblastoma patients treated with a methylating agent.
|
15041700 |
2004 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients with glioblastoma containing a methylated MGMT promoter benefited from temozolomide, whereas those who did not have a methylated MGMT promoter did not have such a benefit.
|
15758010 |
2005 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we tested the hypothesis that MGMT is regulated by p53 in astrocytic cells, the precursors of which may give rise to glioblastoma. p53 is of interest because, in addition to often being mutated in glioblastoma, inactivation sensitizes some astrocytoma cell lines to temozolomide.
|
17234766 |
2007 |
|
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Hypermethylation of the MGMT gene alters DNA repair and is associated with longer survival of glioblastoma patients treated with alkylating agents.
|
17591937 |
2007 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, our findings underline the association of glioblastoma long-term survival with prognostically favourable clinical factors, in particular young age and good initial performance score, as well as MGMT promoter hypermethylation.
|
17785346 |
2007 |
|
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, inhibitors of DNA methylation and histone deacetylation failed to increase MGMT protein levels in the transformed astrocyte cells as well as cultured glioblastoma cell lines, whereas the treatment partially restored mRNA levels.
|
17547775 |
2007 |
|
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Promoter methylation of MGMT gene silencing has been shown to predict benefit from chemotherapy in glioblastoma.
|
17906460 |
2007 |
|
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
|
16609952 |
2007 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These include the importance of O6-methylguanine-DNA-methyltransferase (MGMT) in glioblastoma sensitivity to the DNA alkylating chemotherapy temozolomide.
|
17992094 |
2007 |
|
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT immunohistochemical expression and promoter methylation in human glioblastoma.
|
18091318 |
2008 |
|
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Epigenetic silencing of the DNA repair protein O(6)-methylguanine-DNA methyltransferase (MGMT) by promoter methylation predicts successful alkylating agent therapy, such as with temozolomide, in glioblastoma patients.
|
18556773 |
2008 |
|
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MGMT and GST expression did not predict the sensitivity of glioblastoma cells to alkylating agents.
|
18584351 |
2008 |
|
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma.
|
18004504 |
2008 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Of note, not all patients with glioblastoma having MGMT promoter methylation respond to alkylating agents, and even those who respond will inevitably experience relapse.
|
18757334 |
2008 |
|
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
|
18445844 |
2008 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Association between response to primary treatments and MGMT status in glioblastoma.
|
18983238 |
2008 |
|
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The O(6)-methylguanine DNA methyltransferase (MGMT) gene encodes a DNA repair enzyme whose activity is a major mechanism of resistance to alkylating drugs in glioblastoma treatment.
|
18384736 |
2008 |
|
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Epigenetic inactivation of MGMT has been demonstrated to be a predictive marker for benefit from alkylating agent therapy in glioblastoma.
|
18546261 |
2008 |
|
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status.
|
19188675 |
2009 |
|
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.
|
19011762 |
2009 |
|
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.
|
18952979 |
2009 |
|
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The clinical significance of other glioblastoma-associated molecular aberrations and their relationship to MGMT promoter hypermethylation is still poorly understood.
|
19861461 |
2009 |